Diagnosis of Hypothyroidism
Diagnosis of Hypothyroidism
Diagnosis of Hypothyroidism
secretion
Diagnosis of Hypothyroidism
The lab investigation of hypothyroidism is extremely
simple. Usually clinical assessment, combined with a
single estimation of thyroid hormones and TSH is
sufficient to make diagnosis.
In primary disease, the free T3 and T4 are low and TSH
level raise markedly.
Some labs offer the only the TSH as a 1st line test of
thyroid function though this can result in delayed
diagnosis of secondary and tertiary hypothyroidism,
which should be suspected on the basis of a low free
T4 along with low TSH level.
Elevation of TSH occur in early course of thyroid
failure and may before appearing clinical
manifestation.
Early hypothyroidism may be asymptomatic or
symptoms less obvious and non-specific but a normal
TSH with normal free T4 effeectively excludes the
diagnosis.
A chest radiography may detect the presence of
effusion, and ECG is useful.
All modern TSH assays now employ double antibody
immunometeric techniques, which are robust and
highly reliable. These assays are now so sensitive.
Commercial free T3 and T4 are indirect methods
because both T3 and T4 can be decreased as a non-
specific consequence of systemic illness ( sick
euthyroid syndrome) and depression along with host
of drugs.
Such a patient required specialist assessment and
collaboration with the local lab to rule out confusing
disease and pituitary failure
Treatment
Aim of treatment
Treatment with thyroxine are to ensure that patient receive
a dose that will restore well-being and that usually returns
the TSH level to lower end of the normal range.
In all patient the drug has long half life, it should be given
once daily in the morning.
After 6 weeks thyroid function tests should be checked.
The TSH conc. is the best indicator of thyroid state, and
this should be used for further the dosage adjustment
The raised TSH concentration indicates, inadequate
treatment, poor adherence or both.
The majority of patients will be controlled with dose of
100-200µcg daily with few patient requiring more than
200µcg.
In adult the median dose require to suppress TSH to
normal is 125µcg daily. During pregnancy an increase
in the dose of thyroxine 25-50% is needed to maintain
normal TSH level
Exacerbation of myocardial ischemia, infarction and
sudden death are well-recognized complications of T4
replacement therapy.
Patient with coronary heart disease may be unable to
tolerate full replacement dose because of palpitaions,
angina, or heart failure and elderly patients may have
undiagnosed ischemic heart disease.
In these two group of patients treatment should therefore
started with 25 µcg and increase slowly by 25 µcg evrey 4-6
weeks. During this time clinical progress should be
monitored
In some patients T4 may be better tolerated if β-blocker
such as propranolol is given concomitantly.
It is important to avoid both under and overtreatment.
Hypothyroidism is very rarely life threatening but
adverse effects may result from prolong overtreatment.
Patient Care Plan
Patients on long-term drug therapy are recognized to
have low adherence with medication regimen.
Patients terminate the treatment because they fell well
and think that treatment is no longer required.
Patient should understand the effect of drug holidays
on their health and thyroid function tests and they
should know the normal TSH indicate the adequate
dose.
Written advice should be provided and monitoring of
dosage should continue annually.
Patient information leaflets available on the British
Thyroid Association website at www.british-thyroid-
association.org
Despite the adequate counselling, some patients
persistently forgot to take medicines reliably and other
patient lack capacity of self-medicated reliably.
In these patient weekly dose of T4 is safe and
acceptable to manage them, in whom family or
community staff can supervise treatment.
There are no guidelines yet available, but in practice
patients are normally started with 500-700 µcg
Dosing changes are made in exactly the same way by
assessing TSH levels after 6 weeks of stable dose.